Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC).

Now, an additional analysis of the data has shown the effect enzalutamide also has on health-related quality of life (HRQoL). These criteria include pain and skeletal-related events experienced during the trial.

The researchers utilized the Functional Assessment of Cancer Th